Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: This study presents real-life experience with cefiderocol used on a compassionate basis for treatment of three patients with severe infections caused by extensively/pan-drug resistant (XDR/PDR) Acinetobacter baumannii (Ab).
Methods: Serum bactericidal activity was determined and considered as a surrogate of cefiderocol susceptibility.
Results: Clinical improvement and microbiological eradication of A. baumannii were observed in all three patients, who were affected by extremely complex conditions either for type of infection, adverse effect or resistance profile of A. baumannii.
Conclusion: Cefiderocol for XDR/PDR-Ab infections might be reconsidered, especially in light of the recent disappointing results of the CREDIBLE-CR study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jgar.2020.09.019 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cefepime-zidebactam therapy for extensively drug-resistant and infection as a bridge to liver transplantation.
JAC Antimicrob Resist
August 2025
Division of Infectious Diseases and Center for Infectious Diseases, Houston Methodist Hospital and Houston Methodist Research Institute, Houston, TX, USA.
Background: Infections due to antimicrobial-resistant Gram-negative organisms present increasingly difficult therapeutic challenges, especially in the presence of metallo-β-lactamases. We present the case of a patient with cholangitis due to and isolates that developed cefiderocol resistance on therapy treated successfully with cefepime-zidebactam.
Methods: Serial clinical isolates recovered from biliary fluid and ascitic fluid were tested for susceptibility to cefiderocol, aztreonam-avibactam, cefepime-taniborbactam, cefepime-zidebactam, and cefiderocol-xeruborbactam by broth microdilution.
From genomics to treatment: overcoming pan-drug-resistant in clinical settings.
Front Pharmacol
May 2025
Servicio Antimicrobianos, National Reference Laboratory for Antimicrobial Resistance, Instituto Nacional de Enfermedades Infecciosas, ANLIS "Dr. Carlos Malbrán", Buenos Aires, Argentina.
Introduction: The spread pan-drug resistant pathogens pose a critical challenge to current therapies, resulting in high mortality and necessitating alternative approaches.
Methods: We report pan-drug resistant Klebsiella pneumoniae isolates from five patients in a single hospital, including resistance to cefiderocol and cefepime-zidebactam in one isolate.
Results: Whole-genome sequencing identified blaNDM-5 and blaCTX-M-15 genes in all isolates, explaining carbapenemase and extended-spectrum β- lactamase phenotypes, with blaKPC-2 in one isolate.
Correction: Compassionate use of cefiderocol in a complex case of extensively drug-resistant Acinetobacter baumannii fracture-related infection: a comprehensive approach and multidisciplinary management.
Infection
December 2024
M.I.T.O. (Infections in Traumatology and Orthopedics Surgery) Study Group, Policlinico Umberto I Hospital, Viale del Policlinico 155, 00161, Rome, Italy.
Compassionate use of cefiderocol in a complex case of extensively drug-resistant Acinetobacter baumannii fracture-related infection: a comprehensive approach and multidisciplinary management.
Infection
December 2024
M.I.T.O. (Infections in Traumatology and Orthopedics Surgery) Study Group, Policlinico Umberto I Hospital, Viale del Policlinico 155, 00161, Rome, Italy.
Purpose: Fracture-related infections (FRI) pose a difficult management problem, as they require numerous surgical interventions and extended antibiotic treatments, especially when a multidrug-resistant organism is involved, with a paucity of available literature that provides guidance.
Results: A 42 year-old male presents an open diaphyseal tibia and fibula fracture, complicated by soft tissue necrosis and infections caused by extensively drug-resistant Acinetobacter baumannii (XDR-Ab). Initially treated with a damage control external fixator, the patient underwent multiple surgical procedures, including radical debridement, negative pressure wound therapy, external fixator revisions and reconstructive surgery using a latissimus dorsi free flap.
In Vivo Emergence of Pandrug-Resistant Strain: Comprehensive Resistance Characterization and Compassionate Use of Sulbactam-Durlobactam.
Open Forum Infect Dis
October 2023
Division of Infectious Diseases, Department of Medicine, LSU Health Shreveport, Shreveport, Louisiana, USA.
Article Synopsis
- The treatment of infections caused by carbapenem-resistant bacteria, particularly with emerging resistance to cefiderocol, is difficult and lacks clear solutions.
- A documented case involved successfully treating a patient with pandrug-resistant bacteria using a compassionate use regimen of sulbactam-durlobactam antibiotics.
- Longitudinal genomic analysis revealed the evolution of resistance and genetic mutations in the bacteria over time.